Form D · Other
Notch Therapeutics, Inc.
Vancouver, A1 · CIK 0001847926
Offering snapshot reported Jun 17, 2024 · SEC filing
- Reported sold
- $15.5M Offering amount: $15.5M
- Investors reported
- 16 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 17, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 17, 2024 | Initial | $15,499,990 | No comparison | 16 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-516124
Series B-1 and Series B-2 Preferred Stock, and the Common Stock issuable upon conversion thereof.
Source: Form D, filed Jun 17, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Kamran Alam | Executive |
| Stephen R. Biggar | Director |
| Chris Bond | Executive |
| Bernard Lam | Executive |
| Heather Lee | Director |
| David Main | Director, Executive |
| Ulrik Nielsen | Director |
| Janet Rossant | Director |
| Caroline Stout | Director |
| Emily Titus | Executive |
Issuer details
Industry: Other (See others in industry)
Address:
300 2233 Columbia Street
Vancouver, A1, V5Y 0M6
Vancouver, A1, V5Y 0M6